Arne van Hunnik1, Dennis H Lau1, Stef Zeemering1, Marion Kuiper1, Sander Verheule1, Ulrich Schotten2. 1. Department of Physiology, Faculty of Medicine, Maastricht University, Maastricht, The Netherlands. 2. Department of Physiology, Faculty of Medicine, Maastricht University, Maastricht, The Netherlands. Electronic address: schotten@maastrichtuniversity.nl.
Abstract
BACKGROUND: Vernakalant inhibits several potassium currents and causes a rate- and voltage-dependent inhibition of the sodium current. OBJECTIVE: The aim of this study was to evaluate the antiarrhythmic mechanism of vernakalant in normal and electrically remodeled atria. METHODS: Fourteen goats were instrumented with electrodes on both atria. Drug effects on refractory period (ERP), conduction velocity (CV), and atrial fibrillation cycle length (AFCL) were determined in normal goats (control) and after 2 (2dAF) or 11 (11dAF) days of pacing-induced atrial fibrillation (AF) in awake goats. To evaluate the contribution of changes in conduction and ERP, the same experiments were performed with flecainide and AVE0118. In a subset of goats, monophasic action potentials were recorded during anesthesia. RESULTS: Vernakalant dose-dependently prolonged ERP and decreased CV in CTL experiments. Both effects were maintained after 2dAF and 11dAF. After 11dAF, conduction slowed down by 8.2 ± 1.5 cm/s and AFCL increased by 55 ± 3 ms, leading to AF termination in 5 out of 9 goats. Monophasic action potential measurements revealed that ERP prolongation was due to enhanced postrepolarization refractoriness. During pacing, vernakalant had comparable effects on CV as flecainide, while effect on ERP was comparable to AVE0118. During AF, all compounds had comparable effects on median AFCL and ERP despite differences in their effects on CV during pacing. CONCLUSION: The antiarrhythmic effect of vernakalant in the goat, at clinically relevant plasma concentrations, is based on both conduction slowing and ERP prolongation due to postrepolarization refractoriness. These electrophysiological effects were not affected by long-term electrical remodeling of the atria.
BACKGROUND:Vernakalant inhibits several potassium currents and causes a rate- and voltage-dependent inhibition of the sodium current. OBJECTIVE: The aim of this study was to evaluate the antiarrhythmic mechanism of vernakalant in normal and electrically remodeled atria. METHODS: Fourteen goats were instrumented with electrodes on both atria. Drug effects on refractory period (ERP), conduction velocity (CV), and atrial fibrillation cycle length (AFCL) were determined in normal goats (control) and after 2 (2dAF) or 11 (11dAF) days of pacing-induced atrial fibrillation (AF) in awake goats. To evaluate the contribution of changes in conduction and ERP, the same experiments were performed with flecainide and AVE0118. In a subset of goats, monophasic action potentials were recorded during anesthesia. RESULTS:Vernakalant dose-dependently prolonged ERP and decreased CV in CTL experiments. Both effects were maintained after 2dAF and 11dAF. After 11dAF, conduction slowed down by 8.2 ± 1.5 cm/s and AFCL increased by 55 ± 3 ms, leading to AF termination in 5 out of 9 goats. Monophasic action potential measurements revealed that ERP prolongation was due to enhanced postrepolarization refractoriness. During pacing, vernakalant had comparable effects on CV as flecainide, while effect on ERP was comparable to AVE0118. During AF, all compounds had comparable effects on median AFCL and ERP despite differences in their effects on CV during pacing. CONCLUSION: The antiarrhythmic effect of vernakalant in the goat, at clinically relevant plasma concentrations, is based on both conduction slowing and ERP prolongation due to postrepolarization refractoriness. These electrophysiological effects were not affected by long-term electrical remodeling of the atria.
Authors: Merle Friederike Fenner; Helena Carstensen; Sarah Dalgas Nissen; Eva Melis Hesselkilde; Christine Scott Lunddahl; Maja Adler Hess Jensen; Ameli Victoria Loft-Andersen; Stefan Michael Sattler; Pyotr Platonov; Said El-Haou; Claire Jackson; Raymond Tang; Robert Kirby; John Ford; Ulrich Schotten; James Milnes; Ulrik Svane Sørensen; Thomas Jespersen; Rikke Buhl Journal: Br J Pharmacol Date: 2020-06-24 Impact factor: 8.739
Authors: Márcia Vagos; Ilsbeth G M van Herck; Joakim Sundnes; Hermenegild J Arevalo; Andrew G Edwards; Jussi T Koivumäki Journal: Front Physiol Date: 2018-09-04 Impact factor: 4.566
Authors: Vladimír Sobota; Giulia Gatta; Arne van Hunnik; Iris van Tuijn; Marion Kuiper; James Milnes; Thomas Jespersen; Ulrich Schotten; Sander Verheule Journal: Front Pharmacol Date: 2021-01-27 Impact factor: 5.810
Authors: Jonas Goldin Diness; Lasse Skibsbye; Rafel Simó-Vicens; Joana Larupa Santos; Pia Lundegaard; Carlotta Citerni; Daniel Rafael Peter Sauter; Sofia Hammami Bomholtz; Jesper Hastrup Svendsen; Søren-Peter Olesen; Ulrik S Sørensen; Thomas Jespersen; Morten Grunnet; Bo Hjorth Bentzen Journal: Circ Arrhythm Electrophysiol Date: 2017-10
Authors: Helena Carstensen; Eva Zander Hesselkilde; Maria Mathilde Haugaard; Mette Flethøj; Jonas Carlson; Steen Pehrson; Thomas Jespersen; Pyotr G Platonov; Rikke Buhl Journal: J Cardiovasc Electrophysiol Date: 2019-01-28